TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)
$14.99
+$0.02(+0.13%)
44
Overall
60
Value
30
Tech
44
Quality
Market Cap
$46.83B
Volume
1.75M
52W Range
$12.80 - $15.56
Target Price
$16.67
Order:
Income Statement
| Metric | Trend | Chart | 2024 Mar | 2025 Mar |
|---|---|---|---|---|
| REVENUE | ||||
| Total Revenue | $4263.8B | $4581.6B | ||
| Total Revenue | $4263.8B | $4581.6B | ||
| COST OF GOODS SOLD | ||||
| Cost of Revenue | $1426.7B | $1580.2B | ||
| GROSS PROFIT | ||||
| Gross Profit | $2837.1B | $3001.3B | ||
| OPERATING EXPENSES | ||||
| Operating Expenses | $2416.5B | $2452.0B | ||
| Research & Development | $729.9B | $730.2B | ||
| Research Expense | $729.9B | $730.2B | ||
| Selling, General & Administrative | $1053.8B | $1104.8B | ||
| Selling & Marketing Expenses | $1053.8B | $1104.8B | ||
| Depreciation & Amortization | $652.1B | $643.2B | ||
| Depreciation & Amortization | $652.1B | $643.2B | ||
| Amortization | $652.1B | $643.2B | ||
| Other Operating Expenses | $-19.4B | $-26.2B | ||
| OPERATING INCOME | ||||
| Operating income | $420.6B | $549.3B | ||
| EBITDA | $1000.6B | $1146.5B | ||
| NON-OPERATING ITEMS | ||||
| Interest Expense (Non-Operating) | $219.8B | $210.1B | ||
| Intinc | $52.1B | $46.5B | ||
| Net Non-Operating Interest Income/Expense | $-167.8B | $-163.5B | ||
| Other Income/Expense | $-6.5B | $4.0B | ||
| Other Special Charges | $19.3B | -- | ||
| SPECIAL ITEMS | ||||
| Restructring And Mn A Income | $81.4B | -- | ||
| Special Income Charges | $-206.5B | $-206.7B | ||
| Other Impairment Of Capital Assets | $1.7B | -- | ||
| PRE-TAX INCOME | ||||
| EBIT | $272.6B | $385.1B | ||
| Pre-Tax Income | $52.8B | $175.1B | ||
| INCOME TAX | ||||
| Tax Provision | $91.4B | $66.9B | ||
| NET INCOME | ||||
| Net Income | $-38.7B | $107.9B | ||
| Net Income (Continuing Operations) | $-38.6B | $108.1B | ||
| Net Income (Discontinued Operations) | $-38.7B | $107.9B | ||
| Net Income (Common Stockholders) | $-38.7B | $107.9B | ||
| Normalized Income | $258.8B | $380.1B | ||
| TOTALS | ||||
| Total Expenses | $3843.2B | $4032.2B | ||
| SHARE & EPS DATA | ||||
| Average Shares Outstanding | $3.1B | $3.2B | ||
| Average Shares Outstanding (Diluted) | $3.2B | $3.2B | ||
| Shares Outstanding | $3.1B | $123.5M | ||
| Basic EPS | $46.04 | $34.18 | ||
| Basic EPS (Continuing Operations) | $46.04 | $34.18 | ||
| Diluted EPS | $45.58 | $33.62 | ||
| Diluted EPS (Continuing Operations) | $45.58 | $33.62 | ||
| Dividend Per Share | $47 | $49 | ||
| OTHER METRICS | ||||
| Earnings from equity interest | $6.5B | $-4.0B | ||
| Earnings From Equity Interest Net Of Tax | $6.5B | $-4.0B | ||
| Gain On Sale Of Business | $7.8B | -- | ||
| Gain On Sale Of P P E | $144.0M | -- | ||
| Minority Interests | $-130.0M | $-215.0M | ||
| Other Costof Revenue | $1426.7B | $1580.2B | ||
| Othspecchg | $206.5B | $206.7B | ||
| Restruct | $81.4B | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TAK | $14.99 | +0.1% | 1.75M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW